Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11803827 | 0.85 | KDM4E (0.67) | MYCKDM4ESMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL729994 | 0.85 | SMN1; SMN2 (0.70) | MYCKDM4ESMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL31619607 | 0.85 | KDM4E (0.66) | MYCKDM4ESMN1; SMN2POLBHSD17B10 | |
| SCHEMBL377804 | 0.85 | MYC (0.58) | MYCKDM4ESMN1; SMN2POLBHTT | |
| SCHEMBL2499018 | 0.85 | KDM4E (0.66) | MYCKDM4ESMN1; SMN2POLBHSD17B10 | |
| SCHEMBL30076649 | 0.85 | KDM4C (0.62) | MYCKDM4ESMN1; SMN2POLBHSD17B10 | |
| SCHEMBL170522 | 0.85 | KDM4C (0.62) | MYCKDM4ESMN1; SMN2POLBHSD17B10 | |
| SCHEMBL976774 | 0.85 | MPO (0.58) | MYCKDM4ESMN1; SMN2POLBHTT | |
| SCHEMBL11804736 | 0.83 | SMN1; SMN2 (0.68) | MYCKDM4ESMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL258439 | 0.83 | MYC (0.56) | MYCKDM4ESMN1; SMN2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019073431-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST AND ITS INTERMEDIATE | Piramal Enterprises Limited (IN) | 2019-04-18 | — | — | WO | claimed |
| US-5830931-A | DYEING SYNTHETIC HYDROPHOBIC MATERIAL | BAYER AKTIENGESELLSCHAFT (DE) | 1998-11-03 | — | — | US | claimed |
| CN-116925381-A | Bimetallic MOF material and preparation method and application thereof | 闽南科技学院 | 2023-10-24 | — | — | CN | disclosed |
| WO-2019073431-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST AND ITS INTERMEDIATE | Piramal Enterprises Limited (IN) | 2019-04-18 | — | — | WO | disclosed |
| US-RE45685-E1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| US-8030343-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-7678825-B2 | Pharmaceutically active isoindoline derivates | CELGENE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1228071-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
| EP-0780444-B1 | Process to manufacture polycyclic compounds | BAYER AG (DE) | 2001-09-05 | — | — | EP | disclosed |
| EP-0639624-A1 | Phthaloperinone dyestuffs | BAYER AG (DE) | 1995-02-22 | — | — | EP | disclosed |
| US-5300479-A | Pre-and postemergence herbicides | AMERICAN CYANAMID COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| US-5252560-A | Cyclic imide derivatives, compositions and use | GLAXO INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5108485-A | Controlling monocotyledonous and dicotyledonous plants | AMERICAN CYANAMID COMPANY (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0474991-A1 | Herbicidal 2-(2-imidazolin -2-yl)-benzazoles | AMERICAN CYANAMID COMPANY (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4492796-A | Isoindolenine derivatives, processes for their preparation and their use as intermediate products for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1985-01-08 | — | — | US | disclosed |
| US-4088651-A | Acylamino quinophthalone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-09 | — | — | US | disclosed |
| US-3966726-A | Process for the production of cyclic carboxylic acid imides | AKZO N.V. (NL) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | MYC 3655/4885KDM4E 771/4885SMN1; SMN2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.